Hemophilia B

Hemophilia B, also known as Christmas disease, is an inherited X-linked recessive coagulopathy caused by a deficiency or dysfunction of coagulation factor IX (FIX). It is clinically indistinguishable from hemophilia A (factor VIII deficiency) except by specific factor assays. The disease results in impaired intrinsic pathway activation, leading to defective fibrin clot formation and a bleeding diathesis. Severity is classified based on residual FIX activity: severe (<1% of normal), moderate (1-5%), and mild (6-40%). In veterinary medicine, hemophilia B is most commonly reported in dogs, particularly in certain breeds, and less frequently in cats. The condition is characterized by spontaneous or trauma-induced hemorrhage, which can be life-threatening if not managed appropriately. Early recognition and accurate diagnosis are critical for implementing effective treatment and preventive strategies.

Hemophilia B is caused by mutations in the F9 gene located on the X chromosome. The F9 gene encodes coagulation factor IX, a vitamin K-dependent serine protease zymogen. More than 100 distinct mutations have been identified in dogs, including missense mutations, nonsense mutations, deletions, insertions, and splice-site mutations. These mutations lead to either reduced synthesis of factor IX, production of a dysfunctional protein, or complete absence of the protein. The inheritance pattern is X-linked recessive, meaning that males (XY) are typically affected, while females (XX) are carriers. In rare cases, affected females can occur if the sire is affected and the dam is a carrier. The molecular defect results in impaired activation of factor X by the intrinsic tenase complex (factor IXa, factor VIIIa, calcium, and phospholipid), thereby compromising thrombin generation and fibrin formation. Specific mutations have been identified in breeds such as the Labrador Retriever, Golden Retriever, German Shepherd, and British Shorthair cats, among others.

Hemophilia B is a rare inherited coagulopathy in veterinary medicine, with an estimated prevalence of less than 1% in the general canine population. However, it is more common in certain breeds due to founder effects and selective breeding practices. Breeds with a higher incidence include the Labrador Retriever, Golden Retriever, German Shepherd, Bichon Frise, and Pembroke Welsh Corgi. In cats, the British Shorthair and Siamese breeds have been reported. The disease is typically diagnosed in young animals, often before one year of age, due to spontaneous bleeding episodes or prolonged bleeding after minor trauma or surgery. There is no sex predilection in terms of carrier status, but clinical disease is almost exclusively seen in males. Geographic distribution is worldwide, with no known seasonal variation. Because of the X-linked inheritance, breeding programs can inadvertently propagate the disease if carriers are not identified through genetic testing.

Factor IX is a vitamin K-dependent glycoprotein synthesized in the liver. It circulates as an inactive zymogen and is activated by factor XIa or the tissue factor-factor VIIa complex. Activated factor IX (factor IXa) forms the intrinsic tenase complex with factor VIIIa on phospholipid membranes, which then activates factor X. In hemophilia B, the deficiency or dysfunction of factor IX leads to reduced factor X activation, resulting in decreased thrombin generation and unstable fibrin clots. The coagulation cascade is thus impaired, particularly in the intrinsic pathway, as evidenced by a prolonged activated partial thromboplastin time (aPTT). The extrinsic pathway (prothrombin time, PT) remains normal. The severity of bleeding correlates with the level of residual factor IX activity. Severe deficiency (<1%) results in spontaneous bleeding into joints, muscles, and soft tissues, while mild deficiency may only manifest after trauma or surgery. The pathophysiology also involves impaired platelet plug stabilization, as thrombin is essential for platelet activation and fibrin cross-linking. Recurrent bleeding episodes can lead to chronic joint disease (hemophilic arthropathy) and muscle contractures.

The primary predisposing factor is genetic inheritance, specifically the presence of a mutated F9 gene on the X chromosome. Male dogs and cats are predominantly affected, while females are carriers. Breed predisposition is significant, with certain breeds having a higher prevalence due to historical breeding practices. Environmental factors such as trauma, surgery, or invasive procedures can precipitate bleeding episodes. Concurrent conditions that affect hemostasis, such as thrombocytopenia, von Willebrand disease, or liver disease, can exacerbate the bleeding tendency. Medications that interfere with platelet function (e.g., non-steroidal anti-inflammatory drugs) or coagulation (e.g., warfarin) should be avoided. Stress and strenuous exercise may also increase the risk of spontaneous hemorrhage. In breeding programs, failure to perform genetic screening can lead to inadvertent propagation of the disease.

Clinical signs of hemophilia B vary depending on the severity of factor IX deficiency. In severe cases, spontaneous bleeding may occur without apparent trauma. Common bleeding sites include joints (hemarthrosis), muscles, subcutaneous tissues, and the gastrointestinal or urinary tracts. Affected animals may present with lameness, joint swelling, and pain due to hemarthrosis. Subcutaneous hematomas may appear as fluctuant swellings. Bleeding into the oral cavity, such as from tooth eruption or minor trauma, can be profuse. In neonates, umbilical bleeding may be observed. In moderate to mild cases, bleeding may only occur after trauma, surgery, or dental procedures. Prolonged bleeding from wounds or injection sites is a common presenting complaint. In severe cases, life-threatening hemorrhage can occur into the central nervous system, thoracic cavity, or abdomen, leading to acute collapse, dyspnea, or abdominal distension. Chronic recurrent bleeding can result in anemia, lethargy, and weight loss. Physical examination may reveal pale mucous membranes, tachycardia, and signs of hypovolemic shock in acute blood loss.

Differential diagnoses for hemophilia B include other inherited coagulopathies such as hemophilia A (factor VIII deficiency), von Willebrand disease, and factor VII deficiency. Acquired coagulopathies such as vitamin K antagonism (rodenticide toxicity), liver disease, disseminated intravascular coagulation (DIC), and thrombocytopenia must also be considered. Additionally, conditions causing vascular fragility or platelet dysfunction, such as thrombopathia or vasculitis, may present with similar bleeding signs. Key distinguishing features: Hemophilia A and B are both X-linked and present with prolonged aPTT and normal PT, but specific factor assays (factor VIII and factor IX) differentiate them. Von Willebrand disease typically presents with mucosal bleeding and prolonged buccal mucosal bleeding time, with normal aPTT and PT, and low von Willebrand factor antigen levels. Vitamin K antagonism results in prolonged PT and aPTT, with decreased vitamin K-dependent factors (II, VII, IX, X). Liver disease may cause prolonged PT and aPTT, along with other hepatic enzyme abnormalities. DIC is characterized by thrombocytopenia, prolonged PT and aPTT, elevated fibrin degradation products, and low fibrinogen. Thrombocytopenia is identified by low platelet count on CBC. Definitive diagnosis of hemophilia B requires specific factor IX assay.

The diagnostic approach to a suspected bleeding disorder begins with a thorough history and physical examination, focusing on breed, age, sex, and bleeding episodes. Initial screening tests include a complete blood count (CBC) to assess platelet count and anemia, and coagulation panel including prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen. If aPTT is prolonged and PT is normal, a factor deficiency in the intrinsic pathway is suspected. Next, specific factor assays for factor VIII and factor IX should be performed to differentiate hemophilia A from hemophilia B. A factor IX activity level below 40% confirms the diagnosis. Genetic testing for known F9 mutations can be performed for confirmation and carrier detection. Buccal mucosal bleeding time (BMBT) may be prolonged in platelet disorders but is normal in hemophilia. Imaging studies such as radiography or ultrasonography may be used to identify joint effusions, hematomas, or internal bleeding. In cases of acute hemorrhage, a blood transfusion or plasma product may be needed before diagnostic testing is complete. The diagnostic algorithm should also include assessment for other causes of bleeding, such as liver function tests and vitamin K levels, to rule out acquired coagulopathies.

Hematology: Complete blood count may reveal anemia (regenerative or non-regenerative) depending on the severity and chronicity of blood loss. Platelet count is typically normal. Coagulation testing: Prothrombin time (PT) is normal, while activated partial thromboplastin time (aPTT) is prolonged. Fibrinogen levels are normal. Specific factor IX assay shows reduced activity (<40% of normal). Factor VIII assay is normal, distinguishing hemophilia B from hemophilia A. Serum biochemistry: Liver enzymes (ALT, AST, ALP) and bilirubin may be elevated if there is internal bleeding or concurrent liver disease. Blood urea nitrogen (BUN) and creatinine may be elevated in cases of urinary tract bleeding or dehydration. Electrolyte imbalances may occur secondary to vomiting or diarrhea. Urinalysis: Hematuria may be present if there is bleeding into the urinary tract. Proteinuria may be observed. Blood gas analysis: May show metabolic acidosis or alkalosis depending on the severity of blood loss and tissue perfusion. Specific biomarkers: Not routinely used, but D-dimer levels may be elevated in DIC, which is a differential. Genetic testing: PCR-based assays can detect specific F9 mutations.

Radiography: In cases of hemarthrosis, radiographs of affected joints may show soft tissue swelling, joint effusion, and, in chronic cases, degenerative changes such as osteophytes and subchondral bone sclerosis. Thoracic radiographs may reveal pleural effusion or pulmonary hemorrhage in cases of thoracic bleeding. Abdominal radiographs may show organomegaly or loss of serosal detail due to hemoperitoneum. Ultrasonography: Ultrasound is useful for detecting joint effusions, soft tissue hematomas, and internal bleeding. It can identify free fluid in the abdomen or thorax and assess organ parenchyma for hemorrhage. Doppler ultrasound can evaluate vascular integrity. Computed Tomography (CT): CT is valuable for detecting intracranial hemorrhage, which may be suspected in animals with neurological signs. It can also provide detailed imaging of joint and soft tissue structures. Magnetic Resonance Imaging (MRI): MRI is superior for evaluating soft tissue and joint pathology, including chronic hemophilic arthropathy. Endoscopy: Not typically used for diagnosis but may be employed to evaluate gastrointestinal bleeding. Fluoroscopy: May be used to guide joint aspiration or biopsy procedures. Echocardiography: Not directly relevant, but may be used to assess cardiac function in cases of severe anemia or shock.

Cytology: Fine needle aspiration of joint effusions typically reveals blood or serosanguineous fluid with a high red blood cell count and variable numbers of inflammatory cells. In chronic hemarthrosis, hemosiderin-laden macrophages may be present. Histopathology: Not commonly performed for diagnosis, but if a biopsy is obtained from a bleeding site, it may show extravasated red blood cells, hemosiderin deposition, and fibrosis in chronic cases. In the liver, no specific changes are expected unless there is concurrent disease. Special stains such as Prussian blue can highlight hemosiderin. Histopathology is more useful for ruling out other causes of bleeding, such as vasculitis or neoplasia.

The primary treatment for acute bleeding episodes in hemophilia B is replacement of factor IX. Fresh frozen plasma (FFP) is commonly used, as it contains factor IX. The recommended dose is 10-20 ml/kg IV, repeated every 8-12 hours until bleeding stops. Cryoprecipitate is not effective for hemophilia B because it lacks factor IX. In severe cases, recombinant factor IX or plasma-derived factor IX concentrates may be used, but availability is limited in veterinary medicine. Supportive care includes rest, cold therapy to affected joints, and analgesics (avoiding NSAIDs). In cases of severe anemia, whole blood transfusion may be necessary. For surgical procedures, prophylactic factor IX replacement should be administered before and after surgery. Desmopressin (DDAVP) is not effective for hemophilia B. Antifibrinolytic agents such as tranexamic acid (10-15 mg/kg PO q8h) or epsilon-aminocaproic acid (500 mg/kg PO q6h) may be used as adjunctive therapy to stabilize clots. In the long term, affected animals should be restricted from high-risk activities and trauma. Genetic counseling is essential to prevent propagation of the disease.

The prognosis for hemophilia B varies depending on the severity of factor IX deficiency and the quality of care. Animals with severe deficiency (<1% factor IX) have a guarded prognosis, as they are at risk for spontaneous, life-threatening bleeding. With prompt and appropriate treatment, many animals can survive acute episodes, but recurrent bleeding can lead to chronic joint disease and reduced quality of life. Moderate deficiency (1-5%) carries a fair prognosis, with bleeding typically occurring after trauma or surgery. Mild deficiency (6-40%) has a good prognosis, with bleeding only after significant trauma or invasive procedures. The overall mortality rate is significant, especially in the first year of life. Carrier females have a normal lifespan and no bleeding tendency. Advances in genetic testing and breeding management can reduce the incidence of the disease.

Follow-up care for animals with hemophilia B involves regular monitoring for signs of bleeding and management of chronic complications. Re-check appointments should be scheduled every 3-6 months for a physical examination and CBC to assess for anemia. Coagulation testing, including aPTT and factor IX activity, should be performed as needed to guide treatment. Owners should be educated to recognize early signs of bleeding and seek immediate veterinary care. For animals undergoing surgery, factor IX levels should be monitored perioperatively. Long-term management includes joint care, physical therapy, and pain management for chronic arthropathy. Genetic testing of related animals is recommended to identify carriers and affected individuals. Breeding of affected males and carrier females should be avoided.

Pearls: 1. Hemophilia B is clinically indistinguishable from hemophilia A; specific factor assays are essential for differentiation. 2. aPTT is prolonged, but PT and platelet count are normal. 3. Fresh frozen plasma is the mainstay of treatment; cryoprecipitate is ineffective. 4. Avoid NSAIDs and intramuscular injections in affected animals. 5. Genetic testing is available for many breeds and is crucial for breeding decisions. Pitfalls: 1. Assuming that a normal PT rules out a coagulopathy; aPTT must be evaluated. 2. Using cryoprecipitate for hemophilia B, which lacks factor IX. 3. Failing to consider hemophilia in a female with bleeding; although rare, affected females can occur. 4. Delaying treatment while awaiting diagnostic confirmation; if bleeding is severe, plasma should be administered immediately. 5. Not providing prophylactic factor replacement before surgery, leading to severe hemorrhage.

For acute bleeding: Fresh frozen plasma (FFP) at 10-20 ml/kg IV, repeated q8-12h until bleeding stops. If FFP is unavailable, whole blood may be used. For severe anemia, packed red blood cells at 10-20 ml/kg IV. Antifibrinolytic agents: Tranexamic acid 10-15 mg/kg PO q8h for 3-5 days; epsilon-aminocaproic acid 500 mg/kg PO q6h (max 4 g/day). Analgesics: Avoid NSAIDs; use opioids such as buprenorphine 0.01-0.02 mg/kg IV/IM q8-12h or tramadol 2-5 mg/kg PO q8-12h. For surgical prophylaxis: Administer FFP 10-20 ml/kg IV immediately before surgery, then q8-12h for 24-48 hours postoperatively. In cases of severe deficiency, consider recombinant factor IX (if available) at 20-50 IU/kg IV, repeated as needed. Monitor for volume overload when using plasma products. Adjust dosages in animals with cardiac or renal disease. Contraindications: Avoid drugs that impair platelet function (e.g., aspirin, clopidogrel) and anticoagulants.

Evidence-based literature on hemophilia B in veterinary medicine is limited to case reports, retrospective studies, and breed-specific genetic studies. A retrospective study of 20 dogs with hemophilia B found that the most common clinical signs were lameness and subcutaneous hematomas, and that fresh frozen plasma was effective in controlling bleeding episodes. Genetic studies have identified specific F9 mutations in Labrador Retrievers, Golden Retrievers, and other breeds, enabling DNA-based diagnosis and carrier detection. Consensus guidelines from the ACVIM and ECVIM recommend factor-specific assays for diagnosis and fresh frozen plasma for treatment. There are no large-scale clinical trials due to the rarity of the disease. Future research should focus on gene therapy, which has shown promise in canine models. Overall, the current evidence supports the use of plasma products and supportive care, with genetic testing for breeding management.